CA-JUNIPER-NETWORKS
12.12.2022 15:35:36 CET | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that it has been selected by Deutsche Telekom (DT) as the first network technology partner for Magenta Business Networks SD-X. By leveraging the Juniper AI-driven Enterprise solution, DT’s innovative new universal managed services platform will power exceptional user experiences with simplified zero touch deployments, proactive self-driving automation, connected security and unique client-to-cloud insight.
SD-X is a cloud-based, virtualized and automated platform that will provide a rapid, simplified and cost-effective transition from MPLS to software-defined network services for thousands of European enterprises, including small-to-midsize organizations that might otherwise find the cost and complexity of owned infrastructure to be prohibitive. Juniper is providing DT with advanced technologies to create a secure, software-driven network fabric that uses AI to provide actionable insights on real-time performance coupled with automated mitigation. This approach enables SD-X to deliver optimal user, device and application experiences to its customers as they navigate digital transformation in support of agile, differentiated business capabilities. The managed services offered provide secure networking for campus and branch environments, enabling rich new service functionality and enhanced performance.
News Highlights
- Magenta Business Networks SD-X will leverage Juniper’s full AI-driven Enterprise portfolio, starting with secure SD-WAN and expanding to wired and wireless access.
- The Juniper solution provides client-to-cloud service levels with AI-driven intelligence to optimize and maintain the best user experiences. With AI-driven insight, problems are proactively discovered and addressed via recommended actions and/or self-driving network operations. This minimizes downtime while maximizing end user experiences on the SD-X network.
- Zero touch provisioning with automated workflows enable the SD-X solution services to be pre-configured and easily deployed remotely, saving time and money while minimizing installation errors. The time for new network services to be up-and-running is reduced from weeks or months to just a few days.
- Customers can easily change network policies and security settings remotely at any time using a cloud-hosted SD-X portal, with no manual intervention or site visits needed. Simultaneous updates can be made across a customer’s entire network, so consistent policies are applied between sites.
- By leveraging a microservices cloud, DT can easily update services across the entire Juniper portfolio with little to no downtime.
AI-driven Automation, Insight and Assurance Powers User Experience
The network is the digital lifeblood of today’s enterprise, requiring anywhere, anytime access between users and data. But increased levels of traffic, diversity in devices and distributed location of users can make it extremely challenging to deliver great experiences from client-to cloud. By deploying “smart” AI-driven networking technology from Juniper that can understand user behavior in real-time and automatically optimize the network to lower costs and maximize experiences, SD-X is able to deliver a differentiated and compelling managed service to its subscribers.
Supporting Quotes
“With the relentless pace and demands of modern businesses, our customers need managed services that optimize user experiences while minimizing operational costs. We have built SD-X as a gateway to accessible, progressive enterprise networking without the need for advanced in-house capabilities and technical resources. DT’s vision is made possible thanks to Juniper’s innovation with AI, automation and the cloud, which creates an agile network for our customers that is highly differentiated in the industry.”
- Sherif Rezkalla, VP Portfolio, Head of Business Networks, Deutsche Telekom
“DT has fully embraced the powerful value of intelligent networks with SD-X. This highly-scalable business model is more cost-effective than traditional approaches, while providing the agility and ease of use customers demand. In turn, these customers can use SD-X as the foundation for an experience-driven digital business for their own customers and employees. We look forward to working with DT to roll out more managed services across SD-X to deliver a game-changing networking experience.”
- Manoj Leelanivas, Chief Operating Officer, Juniper Networks
Additional Resources
Case Study: Deutsche Telekom transforms network service delivery
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
